Compare Stocks: TTRX, SANA, TBPH, and PURR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
PURR Hyperliquid Strategies	$6.21 -1.4%	$8.11	$3.01 ▼ $11.62	$910.02M	1.66	8.77 million shs	9.10 million shs
SANA Sana Biotechnology	$3.13 -3.7%	$3.27	$2.61 ▼ $6.55	$904.45M	2.13	2.56 million shs	2.30 million shs
TBPH Theravance Biopharma	$16.86 +0.1%	$16.71	$10.82 ▼ $21.03	$868.67M	0.17	580,184 shs	369,696 shs
TTRX Turn Therapeutics	$8.36 +1.3%	$7.20	$2.57 ▼ $26.50	$245.75M	N/A	135,175 shs	46,540 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
PURR Hyperliquid Strategies	+5.53%	-3.23%	-19.95%	+4.65%	+629,999,900.00%
SANA Sana Biotechnology	+2.52%	+1.25%	-6.88%	-1.22%	-25.46%
TBPH Theravance Biopharma	0.00%	-0.06%	-0.88%	+0.66%	+52.21%
TTRX Turn Therapeutics	+11.04%	-12.97%	+13.01%	+123.58%	+824,999,900.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
PURR Hyperliquid Strategies	$6.21 -1.4%	$8.11	$3.01 ▼ $11.62	$910.02M	1.66	8.77 million shs	9.10 million shs
SANA Sana Biotechnology	$3.13 -3.7%	$3.27	$2.61 ▼ $6.55	$904.45M	2.13	2.56 million shs	2.30 million shs
TBPH Theravance Biopharma	$16.86 +0.1%	$16.71	$10.82 ▼ $21.03	$868.67M	0.17	580,184 shs	369,696 shs
TTRX Turn Therapeutics	$8.36 +1.3%	$7.20	$2.57 ▼ $26.50	$245.75M	N/A	135,175 shs	46,540 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
PURR Hyperliquid Strategies	+5.53%	-3.23%	-19.95%	+4.65%	+629,999,900.00%
SANA Sana Biotechnology	+2.52%	+1.25%	-6.88%	-1.22%	-25.46%
TBPH Theravance Biopharma	0.00%	-0.06%	-0.88%	+0.66%	+52.21%
TTRX Turn Therapeutics	+11.04%	-12.97%	+13.01%	+123.58%	+824,999,900.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
PURR Hyperliquid Strategies	2.50	Moderate Buy	$12.72	104.78% Upside
SANA Sana Biotechnology	2.67	Moderate Buy	$9.50	203.51% Upside
TBPH Theravance Biopharma	2.00	Hold	$19.40	15.07% Upside
TTRX Turn Therapeutics	2.50	Moderate Buy	$8.00	-4.31% Downside

Current Analyst Ratings Breakdown

Latest TTRX, SANA, TBPH, and PURR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/23/2026	SANA Sana Biotechnology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/21/2026	TTRX Turn Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
7/20/2026	TTRX Turn Therapeutics	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/13/2026	TTRX Turn Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (D-)
7/7/2026	TBPH Theravance Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$15.00 ➝ $17.00
7/1/2026	PURR Hyperliquid Strategies	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$8.00 ➝ $18.40
6/29/2026	TTRX Turn Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E)
6/29/2026	TBPH Theravance Biopharma	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
6/29/2026	TBPH Theravance Biopharma	JonesTrading Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold
6/12/2026	PURR Hyperliquid Strategies	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$9.75
6/8/2026	TBPH Theravance Biopharma	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 7/31/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
PURR Hyperliquid Strategies	$1M	897.03	N/A	N/A	$1.52 per share	4.09
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	$0.60 per share	N/A
TBPH Theravance Biopharma	$107.46M	8.09	N/A	N/A	$5.86 per share	2.88
TTRX Turn Therapeutics	N/A	N/A	N/A	N/A	$0.16 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
PURR Hyperliquid Strategies	-$16.01M	-$7.37	N/A	N/A	N/A	N/A	-56.04%	-52.22%	N/A
SANA Sana Biotechnology	-$244.17M	-$0.93	N/A	N/A	N/A	N/A	-108.01%	-40.68%	8/10/2026 (Estimated)
TBPH Theravance Biopharma	$105.89M	$2.20	17.55	62.44	N/A	104.34%	18.84%	10.94%	8/11/2026 (Estimated)
TTRX Turn Therapeutics	-$3.19M	-$0.19	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest TTRX, SANA, TBPH, and PURR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	TBPH Theravance Biopharma	$0.0725	N/A	N/A	N/A	$22.49 million	N/A
8/10/2026	Q2 2026	SANA Sana Biotechnology	-$0.15	N/A	N/A	N/A	N/A	N/A
5/11/2026	Q1 2026	SANA Sana Biotechnology	-$0.15	-$0.14	+$0.01	-$0.17	N/A	N/A
5/11/2026	Q1 2026	TTRX Turn Therapeutics	N/A	-$0.03	N/A	-$0.03	N/A	N/A
5/7/2026	Q3 2026	PURR Hyperliquid Strategies	N/A	$1.01	N/A	$1.01	N/A	$2.63 million
5/7/2026	Q1 2026	TBPH Theravance Biopharma	$0.0280	-$0.10	-$0.1280	-$0.10	$17.78 million	$17.70 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
PURR Hyperliquid Strategies	N/A	N/A	N/A	N/A	N/A
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	N/A
TBPH Theravance Biopharma	N/A	N/A	N/A	N/A	N/A
TTRX Turn Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
PURR Hyperliquid Strategies	N/A	18.23	18.22
SANA Sana Biotechnology	N/A	1.29	1.29
TBPH Theravance Biopharma	N/A	13.14	13.14
TTRX Turn Therapeutics	0.97	2.23	2.23

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
PURR Hyperliquid Strategies	9.45%
SANA Sana Biotechnology	88.23%
TBPH Theravance Biopharma	99.10%
TTRX Turn Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
PURR Hyperliquid Strategies	8.48%
SANA Sana Biotechnology	25.40%
TBPH Theravance Biopharma	7.65%
TTRX Turn Therapeutics	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
PURR Hyperliquid Strategies	N/A	144.45 million	132.20 million	N/A
SANA Sana Biotechnology	380	278.29 million	207.61 million	Optionable
TBPH Theravance Biopharma	110	51.55 million	47.61 million	Optionable
TTRX Turn Therapeutics	2	29.79 million	N/A	N/A

TTRX, SANA, TBPH, and PURR Headlines

Recent News About These Companies

Turn Therapeutics to Ring the Nasdaq Closing Bell on Monday, August 10, 2026

July 28 at 8:01 AM | businesswire.com

Zacks Research Upgrades Turn Therapeutics (NASDAQ:TTRX) to Hold

July 23, 2026 | marketbeat.com

Turn Therapeutics (NASDAQ:TTRX) Upgraded at LADENBURG THALM/SH SH

July 23, 2026 | americanbankingnews.com

LADENBURG THALM/SH SH Upgrades Turn Therapeutics (NASDAQ:TTRX) to Strong-Buy

July 21, 2026 | marketbeat.com

Turn Therapeutics (NASDAQ:TTRX) Upgraded by Wall Street Zen to "Hold" Rating

July 18, 2026 | marketbeat.com

Turn Therapeutics Inc. (TTRX)

July 11, 2026 | sg.finance.yahoo.com

Turn Therapeutics Refines GX-03 Eczema Trial After Interim Data, Eyes 2026 Readout

July 11, 2026 | marketbeat.com

Why Is Turn Therapeutics Stock Trading Higher Today?

July 7, 2026 | benzinga.com

Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis

July 7, 2026 | businesswire.com

Turn Therapeutics to Host Webcast Presenting Comprehensive Interim Analysis and Optimized Stage 2 Design for GX-03 in Atopic Dermatitis

July 6, 2026 | businesswire.com

Turn Therapeutics Stock Short Interest Report | NASDAQ:TTRX | Benzinga

July 3, 2026 | benzinga.com

Turn Therapeutics appoints veteran executive to board

July 3, 2026 | theglobeandmail.com

TTRX Turn Therapeutics Inc.

June 19, 2026 | seekingalpha.com

Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitis

June 1, 2026 | businesswire.com

Turn Therapeutics Announces Peer-Reviewed Publication in Journal of Dermatological Treatment Highlighting GX-03 Activity in IL-36 Associated Inflammatory Model

May 27, 2026 | businesswire.com

Turn Therapeutics to Present at Jefferies Global Healthcare Conference 2026

May 19, 2026 | businesswire.com

Turn Therapeutics Appoints Former FDA Chief to Lead GX-03

May 18, 2026 | tipranks.com

Turn Therapeutics Appoints Physician-Scientist and Former FDA Commissioner, Dr. Stephen M. Hahn, as Executive Clinical and Regulatory Lead

May 18, 2026 | businesswire.com

Turn Therapeutics Stock Price History

May 17, 2026 | investing.com

Turn Therapeutics Inc TTRX

May 17, 2026 | morningstar.comM

Turn Therapeutics Announces Corporate and Pipeline Updates and 2026 Outlook Ahead of the 44th Annual J.P. Morgan Healthcare Conference

May 14, 2026 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TTRX, SANA, TBPH, and PURR Company Descriptions

Hyperliquid Strategies NASDAQ:PURR

$6.21 -0.09 (-1.43%)

Closing price 04:00 PM Eastern

Extended Trading

$6.14 -0.07 (-1.19%)

As of 07:59 PM Eastern

Hyperliquid Strategies Inc is a digital asset treasury company whose primary focus is to maximize shareholder value through accumulating HYPE, the native token of Hyperliquid, a high-performance blockchain custom-built to house all of finance. Hyperliquid Strategies Inc, formerly known as Sonnet BioTherapeutics Holdings Inc., is based in NEW YORK.

Sana Biotechnology NASDAQ:SANA

$3.13 -0.12 (-3.69%)

Closing price 04:00 PM Eastern

Extended Trading

$3.11 -0.02 (-0.64%)

As of 07:39 PM Eastern

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

Theravance Biopharma NASDAQ:TBPH

$16.86 +0.01 (+0.06%)

Closing price 04:00 PM Eastern

Extended Trading

$16.86 +0.00 (+0.03%)

As of 05:21 PM Eastern

Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com.

Turn Therapeutics NASDAQ:TTRX

$8.36 +0.11 (+1.33%)

Closing price 04:00 PM Eastern

Extended Trading

$8.36 0.00 (0.00%)

As of 07:34 PM Eastern

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events. Our proprietary platform has been validated across multiple FDA-cleared medical devices. Our primary development programs focus on dermatological diseases, including moderate to severe eczema and onychomycosis. Our company’s origin is rooted in the personal journey of our founder, who developed a topical ointment to heal his own chronic, treatment-resistant wounds using the PermaFusion platform he developed. His initial formulation, now known as Hexagen (“Hexagen”) suspends certain antimicrobial/anti-inflammatory compounds in petrolatum without known cytotoxicity, irritation or sensitization. This formula has received three FDA clearances and has been utilized extensively in humans, which we believe demonstrates both technical proof of concept and meaningful therapeutic effects. The formula also has been demonstrated to provide anti-inflammatory immunological signaling (IL 36, IL 31, IL 4 inhibition), in-vivo nail penetration with fungal pathogen elimination, and other potential therapeutic benefits. These products are not presently on the market, and we are not currently generating revenue from these devices, as we focus on drug development of our core technology. In addition to our dermatology and wound programs, we are exploring broader applications of our PermaFusion technology. In partnership with a leading global nonprofit organization, we are attempting to develop intranasal vaccines with sufficient thermostability to withstand distribution without deep-freeze. Our goal is to eliminate the need for frozen storage and, thus, enable deployment and delivery to low-resource settings that do not maintain suitable cold storage infrastructure required for administration of modern-day vaccines. Furthermore, if we are successful in this initial program, we believe there may be opportunities to develop additional vaccines in thermostable, intranasal form. By reducing cold-storage infrastructure requirements and therefore enabling standard shipping of such vaccines, we believe intranasal vaccines have the potential to enhance patient uptake by enabling immunization in a broader variety of settings including in clinic, hospital and home-health settings. We believe this initiative highlights our platform’s versatility and its potential to unlock new therapeutic categories beyond dermatology. We have also completed preclinical, in-vivo xenograft studies for herpes zoster ophthalmicus (shingles of the eye) and basal cell carcinoma. A mildly reformulated version of the Hexagen formula was employed for the ocular study and compared this reformulation with placebo as a topical ocular agent intended to reduce viral load of herpes zoster in an animal model. Results obtained showed an 85% reduction in viral load compared to placebo without adverse events. For the basal cell carcinoma xenograft study, the Hexagen formula was compared to both placebo and 5-Fluorouracil (standard of care topical chemotherapy) as a topical treatment intended to reduce basal cell tumor size. The Hexagen formula showed an approximate 29% comparative reduction in tumor size to the placebo and an approximate 20% comparative reduction in tumor size compared to 5-Fluorouracil. We believe these preclinical in-vivo studies suggest meaningful potential in these indications, which we may continue to explore at the conclusion of our lead drug programs. We believe such exploratory results further underscore the potential breadth of opportunity enabled by our platform. We were initially formed on January 6, 2015, as Global Health Solutions, LLC, a Delaware limited liability company. On October 12, 2018, Global Health Solutions, LLC converted to a Delaware corporation under the name Global Health Solutions, Inc., dba Turn Therapeutics. Immediately prior to the effectiveness of the registration statement of which this prospectus forms a part, we intend to change our name to Turn Therapeutics Inc. Our principal executive offices are located in Westlake Village, CA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TTRX, SANA, TBPH, and PURR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TTRX, SANA, TBPH, and PURR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TTRX, SANA, TBPH, and PURR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TTRX, SANA, TBPH, and PURR Company Descriptions

Hyperliquid Strategies NASDAQ:PURR

Sana Biotechnology NASDAQ:SANA

Theravance Biopharma NASDAQ:TBPH

Turn Therapeutics NASDAQ:TTRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TTRX, SANA, TBPH, and PURR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TTRX, SANA, TBPH, and PURR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TTRX, SANA, TBPH, and PURR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TTRX, SANA, TBPH, and PURR Company Descriptions

Hyperliquid Strategies NASDAQ:PURR

Sana Biotechnology NASDAQ:SANA

Theravance Biopharma NASDAQ:TBPH

Turn Therapeutics NASDAQ:TTRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools